Markets◆ Mixed
Strand eyes US, Southeast Asia mkts for blood-based cancer screening test
· BS Companies
Reliance-backed genomics company is pursuing US FDA approval for CancerSpot and aims to cut its price in India to below ₹10,000 over the next two to three years.
In this story
Related coverage
- 74 out of every 100 festive consumer loans are for mobile phones: What is driving India's EMI boom?Markets · 19 Nov 2026 · Business Today Mkts
- Top stocks to watch today: Coal India, Jio Financial, NALCO, Bharat Forge, Sky Gold, Dalmia Bharat and 7 others in focusMarkets · 19 Nov 2026 · LiveMint Markets
- Newly-listed companies add ₹32-trillion to BSE market-cap in 2026Markets · 20 Nov 2026 · Business Standard Mkts
- US-China chip war escalates: How new restrictions could reshape the global AI industryWorld · 21 Nov 2026 · Business Today Mkts
- RIL, SAIL, IndusInd Bank among top upgrades, TMPV, Waaree, ACC among top downgrades post Q2Companies · 20 Nov 2026 · Business Today Mkts
- Reliance Industries shares: After 13% surge in 1 month, JPMorgan sees another 23% upside in Mukesh Ambani stock | TargetCompanies · 19 Nov 2026 · LiveMint Markets
More in Markets
All Markets news →- Hero FinCorp aims to double loan disbursements over next two quartersMarkets · 21 Nov 2026 · BS Companies
- Avengers: Doomsday Advance Bookings: Marvel Fans Turn Up The Heat Ahead Of ReleaseMarkets · 21 Nov 2026 · NDTV Profit
- Real Madrid vs Celta Vigo Live Streaming: Likely Lineups; How To Watch La Liga Match On TV, Online In India?Markets · 21 Nov 2026 · NDTV Profit
- What is Bagheera AT1? Adani Defence & Aerospace tests ATGM system in Rajasthan: Check capabilities, specificationsMarkets · 21 Nov 2026 · LiveMint Companies